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 2 
Abstract: 1 
Both immune profiling and tumor budding significantly correlate with colorectal cancer 2 
(CRC) patient outcome,but are traditionally reported independently. This study evaluated the 3 
association and interaction between lymphocytic infiltration and tumor budding, coregistered 4 
on a single slide, in order to determine a more precise prognostic algorithm for patients with 5 
stage II CRC. Multiplexed immunofluorescence and automated image analysis were used for 6 
the quantification of CD3
+
CD8
+
 T cells, and tumor buds (TBs), across whole slide images of 7 
three independent cohorts (training cohort: n = 114, validation cohort 1: n = 56, validation 8 
cohort 2: n = 62). Machine learning algorithms were used for feature selection and prognostic 9 
risk model development. High numbers of TBs (HR = 5.899, 95% CI, 1.875 - 18.55), low 10 
CD3
+
 T cell density (HR = 9.964, 95% CI 3.156 - 31.46), and low mean number of 11 
CD3
+
CD8
+
 T cells within 50 μm of TBs (HR = 8.907, 95% CI 2.834 - 28.0) were associated 12 
with reduced disease-specific survival. A prognostic signature, derived from integrating TBs, 13 
lymphocyte infiltration, and their spatial relationship, reported a more significant cohort 14 
stratification (HR = 18.75, 95% CI 6.46–54.43), than TBs, Immunoscore, or pT stage. This 15 
was confirmed in two independent validation cohorts (HR = 12.27, 95% CI 3.524–42.73, HR 16 
= 15.61, 95% CI 4.692-51.91). The investigation of the spatial relationship between 17 
lymphocytes and TBs within the tumor microenvironment improves accuracy of prognosis of 18 
patients with stage II CRC through an automated image analysis and machine learning 19 
workflow.  20 
 3 
Introduction: 1 
Tumor Node Metastasis (TNM) staging remains the gold standard for stratification of 2 
colorectal cancer (CRC) patients into prognostic subgroups, and is fundamental for treatment 3 
selection (1,2). Surgical resection without the use of adjuvant treatment results in long-term 4 
disease-free survival in most stage II CRC cases. However, 20% of patients experience 5 
disease-specific death (3). In addition, some stage III patients experience better outcomes 6 
than some stage II patients. This is in spite of revisions to the TNM guidelines, which, for 7 
example, subdivide pT stage II into three categories (4). Alongside pT stage, tumor 8 
differentiation aids the pathologist in sub-stratifying patients into high or low risk of tumor 9 
progression; however grade is highly subjective (5). Tumor budding, which morphologically 10 
resembles small, poorly-differentiated clusters of cells (1-4 cells) disseminating at the 11 
invasive margin, has consistently been correlated with poor CRC prognosis (6–8). 12 
Both TNM staging and tumor budding concentrate solely on the tumor, but it is now well 13 
established that the host interaction, such as immune infiltrate, within the tumor 14 
microenvironment (TME) plays a crucial role in tumor progression (9,10). Specifically, in 15 
CRC, the pioneering studies of Galon and colleagues demonstrated that CD3
+
 and CD8
+
 T-16 
cell infiltration was an independent prognostic factor predicting patient survival (9,11). 17 
Tumor buds (TBs) are hypothesized to represent a highly invasive tumor subpopulation, 18 
especially if they also have the ability to evade the host immune response (6–8). The 19 
interaction between immune response and TBs may therefore hold vital information 20 
pertaining to the tumor’s potential to metastasize. 21 
Previous research has demonstrated the ability to automatically quantify CD3
+
 and CD8
+
 T 22 
cells within the TME, thereby achieving a greater level of standardization than with 23 
subjective, manual reporting (9). Similarly we have previously shown that tumor budding can 24 
be standardized through automated image analysis (12,13). Although the automatic 25 
quantification of both immune infiltrate and tumor budding has been associated with patient 26 
prognosis, they have not been studied together. Furthermore, by coregistration on the same 27 
tissue section it is possible to accurately study the spatial interaction with each other. We 28 
apply such an approach in this study to investigate if quantifying both features alongside their 29 
spatial interaction allows for a more precise and accurate prognosis for stage II CRC patients.  30 
 4 
Materials and methods 1 
Patient Material and Clinical Data 2 
This study included three independent cohorts of stage II CRC patients who underwent 3 
surgical resection in Edinburgh, UK, hospitals over the years 2002–2004 (n = 170) and the 4 
National Defense Medical College Hospital (NDMCH), Japan, over the years 2006–2011(n = 5 
62). The formalin-fixed paraffin-embedded (FFPE) block that contained the deepest cancer 6 
invasion for each patient was selected after the review of hematoxylin and eosin (H&E) 7 
slides. Cancer blocks from Edinburgh hospitals comprised specimens of cross-sectional cut 8 
whereas the ones from the NDMCH were of longitudinal cut. Associated clinical data 9 
included features from the original pathology report, such as TNM staging and differentiation 10 
as well as detailed follow-up information including disease specific survival (DSS); up to 11 
11.5 years for the Edinburgh cohort and 8.6 years for the Japanese cohort. 114 consecutive 12 
patients who underwent surgical resection in Edinburgh hospitals over the years 2002–2003 13 
were used as a training cohort for this study. All available patients who underwent surgical 14 
resection in Edinburgh hospitals in the following year (2004) were used as a first validation 15 
cohort (n = 56). We then used a similar number of patients who underwent surgical resection 16 
in the NDMCH, Japan over the years 2006–2011 as an international validation set (n = 62). 17 
The clinicopathological data of all the cohorts are shown in Table 1. This study was 18 
conducted in accordance with the declaration of Helsinki. Ethical approval was obtained after 19 
review by the NHS Lothian NRS BioResource, REC-approved Research Tissue Bank (REC 20 
approval ref: 13/ES/0126), granted by East of Scotland Research Ethics Service and by the 21 
Ethics Committee of the National Defense Medical College (approval ref: No.2992). The 22 
ethical approval permitted us to use archival diagnostic samples once they were de-identified 23 
for the purposes of the research. 24 
 25 
Immunofluorescence and Image Capture 26 
Immunohistochemistry antibody optimization 27 
We selected externally validated specific primary antibodies: primary antibody against CD8
+
 28 
cytotoxic T cells (monoclonal mouse anti-human CD8, M7103, Dako, Glostrup, DK) was 29 
previously used for the international validation of the consensus Immunoscore by Pages et 30 
al.(14),  primary antibody against pan T cells (Polyclonal Rabbit Anti-Human CD3, 31 
A045201-2, Dako, Glostrup, DK) used by Harter et al. (15), in assessment of tumor-32 
infiltrating lymphocytes in human brain metastases and for pan-cytokeratin (PanCK) (mouse 33 
monoclonal anti-human cytokeratin, M351501-2, Dako, Glostrup, DK) previously used by 34 
Koelzer et al. (16), for the assessment of TBs in CRC. 35 
In order to assess the in-house antibody performance, each antibody was individually 36 
assessed by brightfield immunohistochemistry (IHC). The primary antibodies against CD3 37 
and CD8 T cells were each tested individually on 3μm thick serial sections of normal tonsil 38 
FFPE tissue, known to have high lymphocytic cell concentration. For assessment of PanCK 39 
primary antibody, a CRC optimizing tissue microarray, consisting of 100 cores taken from 40 
primary tissue blocks, was used. Expression of all cell markers was detected using 3,3’-41 
Diaminobenzidine (DAB) chromogen (K3468, Dako, Glostrup, DK). Nuclei were 42 
counterstained with hematoxylin (RBA-4213-00A, CellPath, Newton, UK). In parallel, H&E  43 
 5 
(RBB-0100-00A, CellPath, Newton, UK) staining was performed on serial sections and 1 
specificity of antibodies from the IHC was assessed and compared visually by an experienced 2 
pathologist (DJH) and research scientists (IPN and PDC). No CD8 positive but CD3 negative 3 
cells were present, giving confidence to the antibodies’ specificity.  Positive and negative 4 
controls were used in each immunohistochemistry staining; human tonsil FFPE tissue without 5 
primary antibody for CD3 and CD8 T cells and a CRC optimizing tissue microarray without 6 
primary antibody for PanCK. Western blot analysis was also used to assess the specificity of 7 
the PanCK antibody using CRC cell lines. 8 
Immunofluorescence staining optimisation 9 
Once specificity of antibodies was confirmed in brightfield, each target was assessed by a 10 
uniplex immunofluorescence. Uniplex immunofluorescence was performed on serial sections 11 
of the CRC optimising tissue microarray (specified above) with the use of individual 12 
tyramide signal amplification (TSA) fluorescence kits. After deparaffinization, slides were 13 
placed in a microwaveable pressure cooker containing boiling antigen retrieval (AR) buffer 14 
(0.1M Sodium Citrate pH6) and microwaved for 5 min at 75 °C. Slides were allowed to cool 15 
down in running tap water for 20min at room temperature and were then rinsed with 0.1% 16 
Phosphate buffered saline-Tween 20 (PBS-T). PBS-T was used for all washing steps. Tissues 17 
were then blocked with 3% hydrogen peroxide for 5 minutes and Dako serum free protein 18 
block (X090930-2, Dako, Glostrup, DK) was then applied for 10 minutes. Slides were then 19 
incubated for 30 min with the same antibodies as for immunohistochemistry at these 20 
dilutions: CD3 (dilution 1:400), CD8 (dilution 1:200) and PanCK (dilution 1:100). Slides 21 
were then washed (3 x 5min). The slides that had previously been incubated with CD3 or 22 
CD8 antibodies were then incubated in pre-diluted anti mouse or anti rabbit HRP conjugated 23 
secondary antibodies (K400111-2 and K400311-2 respectively, Dako, Glostrup, Denmark) 24 
for 30 min. Following 3 more washes of 5 min, slides were incubated for 10 min with either 25 
TSA® fluorescein (FITC) for CD3 antibody visualisation or TSA® Cyanine 5 for CD8 26 
antibody visualisation (NEL741B001KT and NEL745B001KT respectively, Perkin Elmer, 27 
MA, USA) at 1:100 dilution. The slide that had been previously incubated with PanCK 28 
antibody was then incubated in anti-mouse AlexaFluor 555 (A21422, ThermoFisher, MA, 29 
USA) in antibody diluent (S080983-2, Dako, Glostrup, DK) at 1:100 dilution for 30 min. 30 
Finally, following a washing step, the slides were counterstained for 10 min with Hoechst 31 
33342 (H3570, ThermoFisher, MA, USA) at 1:20 dilution in de-ionised water.  Sections were 32 
then dehydrated in 80% ethanol and mounted with ProLong Gold Antifade Reagent (P36930, 33 
Thermo Fisher Scientific Inc., MA, USA). Optimal antibody dilutions in the uniplex 34 
immunofluorescence slides were chosen to ensure best signal to noise and specific staining 35 
pattern when digitised on the Zeiss Axioscan.z1 whole slide scanner (Zeiss, Oberkochen, 36 
DE). Fluorescence slides were compared with serial section of brightfield DAB slides using 37 
the same antibodies. Positive and negative controls were included in each staining run. The 38 
positive controls for the CD3 and CD8 antibodies were the tonsil tissue as specified above. 39 
Once the appropriate dilution of primary antibodies, secondary antibodies and fluorophores 40 
were found under uniplex immunofluorescence, we then assessed them multi-plexed on a 41 
single tissue section. In order to eliminate species cross reactivity, microwave stripping was 42 
performed between the CD8 and PanCK staining. Microwave stripping was performed as 43 
follows. AR buffer was heated in a pressure cooker in the microwave for 12 min prior to 44 
adding the slides in the solution. Slides were then microwaved for 17 min using the auto 45 
defrost function. Sections were then allowed to cool down in running tap water for 20 min 46 
and washed for 5 min. The immunofluorescence protocol utilised to label the study samples 47 
was performed as above using a DAKO Link48 Autostainer (Dako, Glostrup, DK). The first 48 
 6 
run of labelling included the primary antibody against CD8 prior to antibody stripping, and 1 
labelling with a primary antibody cocktail of CD3 and PanCK prior to counterstaining with 2 
Hoechst. The multi-plexed section was compared to the uniplex labelled serial sections and 3 
we confirmed that there was no increase or decrease in the level of specific signals or 4 
nonspecific background signals. 5 
Whole slide fluorescence images were captured with a 20x objective using an Axioscan.Z1 6 
(Zeiss, Oberkochen, DE). Exposure times for Hoechst, Cy3, Cy5 and FITC channels were 12, 7 
120, 8 and 25ms, respectively (see supplementary methods for detailed protocol of antibody 8 
optimization and multiplexed immunofluorescence). 9 
 10 
Digital Image Analysis  11 
Digital whole slide fluorescence images, in Zeiss’ .czi file format, were uploaded into HALO 12 
Next Generation Image Analysis software (version 2.1.1637.18) (IndicaLabs, Corrales, NM) 13 
for image analysis. Full algorithm workflow and settings are shown below: 14 
 15 
Nuclear segmentation: 16 
All nuclei in the whole slide image were automatically segmented using the commercially 17 
available High-Plex FL (version 2.0) module within the HALO Next Generation image 18 
analysis software. Optimized module parameters for nuclei detection included dye weights 19 
(Hoechst nucleus weight = 4, Cy5 nucleus weight = 0.232, FITC nucleus weight = 0.232), 20 
nuclear contrast threshold (0.5), minimum nuclear intensity (0.079), nuclear segmentation 21 
aggressiveness (0.65) and using the default nuclear size setting (1-500µm
2
). All samples were 22 
analyzed using these specific settings. 23 
 24 
Lymphocytic Infiltration Analysis 25 
Within the same software module in which we segmented the nuclei, (High-Plex FL), cells 26 
were then classified as CD3 (FITC) or CD8 (Cy5) positive based on dye nucleus positive 27 
threshold (Cy5 = 0.132, FITC = 0.15), cytoplasm positive threshold (Cy5 = 0.075, FITC = 28 
0.5) and membrane positive threshold (Cy5 = 0.075, FITC = 0.5). The algorithm settings 29 
were kept constant across all patients. Next, the algorithm automatically quantified the 30 
number of each lymphocyte classification across the whole slide image. The flood tool was 31 
used to identify the invasive front. An invasive margin (IM) was created which consisted of a 32 
width span of 500µm in and out from the invasive front. The tumor core area (CT) was set to 33 
be the whole tumor area excluding the 500µm before the invasive front (Fig. 1A). 34 
Lymphocytes (CD3
+
 and CD8
+
 T cells) infiltrating both the CT and the IM of the tumor were 35 
automatically quantified (Fig. 1B) and their densities (cells/ mm²) were exported to assess 36 
their prognostic significance. 37 
 38 
Immunoscore Evaluation 39 
Immunoscore was performed based on the methodology described previously by Galon et 40 
al(9). Using the lymphocytic infiltration analysis results, CD3
+
 and CD8
+
 lymphocytes were 41 
counted in both the IM and CT resulting in the reporting of the following features: CD3
+ 
T 42 
cells in the CT, CD3
+
 T cells in the IM, CD8
+
 cells in the CT and CD8
+
 T cells in the IM. 43 
Optimal cutoff points for the four features were calculated based on survival data of the 44 
 7 
training cohort (Supplementary Table S1). Values above the optimal cutoff points for each 1 
feature were scored 1 whereas values below were scored 0. An immunoscore was then 2 
calculated by the sum of all scores for each patient sample. Finally, similarly to Liu et al. 3 
(17), patients were stratified into two groups; High Immunoscore > 2 and Low Immunoscore 4 
≤ 2.  5 
 6 
Tumor Budding Analysis 7 
The PanCK intensity within each whole slide image was initially assessed using the Area 8 
Quantification FL v1.2 module without any changes to the commercially available module 9 
thresholds. Patient samples were grouped into two categories based on their resulting PanCK 10 
intensity; low (average dye intensity < 2.16 x 10
-2
) and high (average dye intensity > 2.16 x 11 
10
-2
). Using samples from within each PanCK group (high or low), machine learning 12 
classifiers were trained to segment tumor from non-tumor region. Two High Plex FL (version 13 
2.0) modules were next created; one using the classifier trained from low PanCK patient 14 
samples and one from the high PanCK patient samples. Patients with an average PanCK 15 
intensity below 2.16-02 were analyzed to segment tumor from non-tumor using the classifier 16 
termed ‘low PanCK’ and the other with the classifier termed ‘high PanCK’. These modules 17 
were run within a 1000μm border inwards from the invasive front; termed the tumor budding 18 
region of interest (TBROI) (Fig. 1C). Within the tumor regions detected, nuclei were detected 19 
using the methodology described above and cancer cells were classified based on PanCK 20 
positivity in nucleus (0.1), cytoplasm (0.08) and membrane (0.05) (Fig. 1D). These cancer 21 
cell classification thresholds were kept constant across the entire cohort of images. TBs were 22 
classified as tumor clusters containing up to 4 PanCK
+
 cells. TB density (TBs / mm²) and 23 
number were then exported from the algorithm. Mucin pools and areas of necrosis were 24 
excluded. 25 
 26 
Spatial Analysis of Lymphocytes and Tumor Buds 27 
Spatial coordinates of the lymphocytes and TBs were imported into a spatial plot within the 28 
HALO software. From this plot, the Spatial Analysis algorithm was utilized to calculate the 29 
number of CD3
+
 and CD8
+
 T cells within a range between 0-100 μm radii of TBs (Fig. 1E) in 30 
consecutively increasing 10 μm steps therefore creating 11 classes; 0-10 μm, 0-20 μm, 0-30 31 
μm and so on. All classes of radius size were significantly associated with survival, however 32 
after assessing the prognostic significance of iterative groupings of varying radius sizes, there 33 
was a statistical difference observed between the 0-50 μm and the 0-100 μm groupings.  The 34 
classes were therefore merged into two categories: 0-50 μm and 0-100 μm radii of TBs. 35 
Finally, the number and densities of CD3
+
 and CD8
+
 T cells within these distances were 36 
established. 37 
  38 
All features exported from the image analysis are listed in Supplementary Table S2.  39 
 40 
Statistical Analysis 41 
All statistical analysis, unless otherwise stated, was performed in RStudio 1.1.419 running R 42 
3.4.3 (18,19). Continuous image analysis data, categorical clinical data and survival data 43 
were loaded into R. The relationship between lymphocyte distribution patterns, TBs, and 44 
 8 
patient characteristics was assessed using the Chi-Square test. For comparison with 1 
categorical patient data, image analysis features were divided into low and high groups 2 
according to optimal cut-off points based on survival data. To assess the relationship between 3 
lymphocytes and TBs, Spearman correlation coefficients (r) were applied on continuous data. 4 
All r = 0 values indicated no association between features, r > 0 indicated a positive 5 
association where as one variable increases, so does the other and r < 0 indicated a negative 6 
association where as one variable increases the other decreases. Associations between 7 
features were assessed on the training cohort. 8 
Univariate Cox regression was performed on both the categorical clinical and continuous 9 
image analysis data. All P < 0.05 values were considered statistically significant.  10 
The least absolute shrinkage and selection operator (LASSO) penalized Cox proportional 11 
hazard regression was performed for identification of significant features (20), using the 12 
glmnet package (21). The significant features identified by LASSO were then inputted into a 13 
random forest (RF) (n = 500) decision tree model using the randomForest package
 
(22) and 14 
were ranked according to their mean decrease Gini coefficient. Features with a mean decrease 15 
Gini of above 4 were taken forward for further analysis. Optimal cutoff points for these 4 16 
features were calculated and iterative combinations of these features were tested. The model 17 
with most predictive value was then selected; termed the “tumor bud-immuno spatial index” 18 
(TBISI). In order to avoid overfitting during the development of the model, validation was 19 
performed for both LASSO Cox regression model (10-fold cross validation) and random 20 
forest (out of the bag). Univariate Cox regression was performed for; the TBISI, pT stage, TB 21 
number and Immunoscore, and a bootstrap resampling technique was applied (number of 22 
samples = 1000) in SPSS 24 (23). Multivariate Cox Regression with a forward stepwise 23 
method and the Receiver Operating Characteristic (ROC) curve were also applied on to 24 
compare the TBISI, pT stage TB number and Immunoscore in SPSS 24. The prognostic value 25 
of TBISI was then assessed on two independent validation cohorts. All validations were 26 
performed using the fixed optimal cut-off points of the training cohort. All optimal cutoff 27 
points for the categorization of image analysis features including tumor budding, the 28 
immunoscore and for the development of the TBISI were based on disease specific survival 29 
and were calculated using the survminer package (24). All Kaplan Meier (KM) curves were 30 
plotted using the survival package (25). The P values from KM curves were corrected for 31 
false discovery rate (FDR) using the Benjamini-Hochberg procedure to account for multiple 32 
hypothesis testing (26).  33 
Study workflow is illustrated in Supplementary Fig. S1.   34 
 9 
Results 1 
Patient Characteristics 2 
The clinicopathological characteristics of all three cohorts of stage II CRC patients are shown 3 
in Table 1. This study cohort comprised a training cohort of 114 stage II CRC patients, of 4 
which 57 were female and 57 were male. The validation cohorts included 34 male and 22 5 
female patients in validation cohort 1 and 42 male and 20 female patients in validation cohort 6 
2. The range of patients’ age was 37–96 years old. There were 43 right-sided colon 7 
carcinomas, 38 left-sided and 33 rectal cancers in the training cohort and 29 and 14 right-8 
sided colon carcinomas, 9 and 22 left-sided and 18 and 26 rectal cancers in validation cohort 9 
1 and 2, respectively. 10 
Correlations of Patient Characteristics with Lymphocyte Density and TB Number 11 
Automated image analysis was performed to quantify TBs (within TBROI), CD3
+
 cell, and 12 
CD8
+
 T-cell densities (within IM and CT). Optimal cutoff points based on survival data were 13 
used to categorize image analysis features of the training cohort into low and high groups 14 
(Supplementary Table S1). TB number and density were highly correlated with each other 15 
(correlation coefficient = 0.7466; P < 2.2 x 10
-16
; therefore, TB number was selected to be 16 
used for correlation assessments. The relationship between patient characteristics and both 17 
lymphocyte distribution patterns and TB number was then assessed. A high density of CD3
+
 18 
T cells at the IM was associated with no extramural lymphovascular invasion (EMLVI; P = 19 
0.049), whereas in the CT it was correlated with moderate differentiation status and non-20 
mucinous histological type (P = 0.007 and P = 0.023, respectively). A high density of CD8
+
 21 
cells at the IM and across the whole tumor section (WTS) was significantly associated with 22 
female gender (P = 0.016 and P = 0.030 respectively). Finally, advanced pT stage was 23 
significantly associated with a high TB number at the TBROI (P = 0.031) (Table 2). 24 
Relationship between Tumor Budding and Lymphocyte Density  25 
TB number was tested for association with lymphocyte densities of the training cohort, using 26 
the Spearman correlation coefficient (Fig. 2). This indicated a weak negative relationship 27 
between TB number and all lymphocytic cell densities (r < 0) regardless of distribution 28 
pattern (ie. IM, CT, WTS) or lymphocytic cell subpopulations (CD3
+
 or CD8
+
). However, a 29 
higher density of CD3
+
 T cells at the IM, CD8
+
 T cells at the IM, and WTS were significantly 30 
correlated with a lower TB number (P = 0.016, P = 0.037, and P = 0.041 respectively) 31 
(Supplementary Table S3). 32 
Survival Analysis - Clinicopathological Data 33 
To assess the prognostic significance of the categorical clinicopathological data of the 34 
training cohort, univariate Cox-regression was applied. KM survival analysis was used to 35 
further assess any significant prognostic features from the clinicopathological data of the 36 
training cohort (Fig. 3). Univariate Cox-regression showed that only pT stage (HR =4.143; 37 
95% CI, 1.480-11.570; P = 0.006) was significantly associated with disease specific survival 38 
(Table 1). KM survival function was then applied and showed that patients of T4 stage have 39 
poor DSS (73% survived) compared to T3 stage patients (91% survived) (P = 0.003) (Fig. 40 
3A). 41 
 10 
Survival Analysis - Image Analysis Features 1 
To explore the prognostic effects of the quantified lymphocytic distribution patterns, TB 2 
number and density within the training cohort, we performed univariate Cox-regression 3 
analysis. This analysis was also performed for the spatial relationships between lymphocytes 4 
and TBs. The following specific continuous features were calculated and exported from the 5 
image analysis algorithm: a) in IM, CT and WTS; densities of CD3
+
 and CD8
+
 T cells and 6 
ratio of CD3
+
 to CD8
+
 T cells; b) TB number and density at the TBROI, c) within 0–50 μm 7 
and 0–100 μm radius of TBs; number and mean number of CD3+ and CD8+ T cells. The 8 
densities of both CD3
+
 and CD8
+
 T cells were significantly associated with disease specific 9 
survival (P < 0.05). TB number and density conferred prognostic significance (HR =1.001; 10 
95% CI, 1.000–1.001; P = 0.0004 and HR =1.030; 95% CI, 1.000–1.060; P = 0.0446 11 
respectively). KM analysis showed TB number to be a significant prognostic factor; 95% of 12 
patients in the low tumor budding group survived compared to the high tumor budding group, 13 
in which 73% of patients survived (P = 0.0006) (Fig. 3D). Furthermore, a high mean number 14 
of lymphocytes near TBs was significant in predicting disease specific survival for stage II 15 
CRC patients (P < 0.05) (Supplementary Table S2). 16 
Significant Feature Selection 17 
All clinicopathological and image analysis data of the training cohort (listed in 18 
Supplementary Table S2) were input for a LASSO penalized Cox proportional hazard 19 
regression. This was performed to identify the features that add significant value to the 20 
prediction of disease specific survival over time and therefore to reduce the data 21 
dimensionality. The analysis reported that there were 8 significant candidate features (CD3
+
 22 
T-cell density at WTS, mean CD3
+
CD8
+
 T-cell number within 0–50 μm of TBs, TB Number, 23 
CD8
+
 T-cell density in CT, pT stage, EMLVI, age, and differentiation). The 8 features which 24 
added value to the model were used as further input into a RF decision tree model for optimal 25 
prognostic feature selection. The RF model reported 4 features with a mean decrease Gini of 26 
above 4 (CD3
+
 T-cell density in WTS, mean CD3
+
CD8
+
 T-cell number within 0–50 μm of 27 
TBs, TB number, CD8
+
 T-cell density in CT) (Table 3). 28 
Development of Tumor Bud Immuno-Spatial Index 29 
Optimal cutoff points for these 4 features (CD3
+
 T-cell density in WTS, mean CD3
+
CD8
+
 T-30 
cell number within 0–50 μm of TBs, TB number, CD8+ T-cell density in CT) were calculated 31 
for the training cohort using the patient survival data (389.6 cells/mm
2
, 4.1, 1104.0, and 114.7 32 
cells/mm
2
, respectively). The least significant feature was then removed in an iterative 33 
process until the removal of a feature decreased the prognostic value of the model. This led to 34 
the creation of the TBISI consisting of 3 features; CD3
+
 T-cell density in WTS, mean 35 
CD3
+
CD8
+
 T-cell number within 0–50 μm of TBs and TB number. Patients with CD3+ T-cell 36 
density in WTS and mean CD3
+
CD8
+
 T-cell number within 0–50 μm of TBs below the cutoff 37 
point and TB number above the cutoff point were classified as a “high risk” of disease 38 
specific death group; the remainder of the patients were classified as a “low-risk” group. KM 39 
curves and bootstrap univariate cox regression p values were used to determine the 40 
significance of this index. The created TBISI was highly significant in the prediction of 41 
disease specific death from both KM analysis and cox regression (HR = 18.75, 95%CI 6.46-42 
54.43; p = 1.202 x 10
-13
) (Fig. 3J). KM and univariate cox-regression analyses were also 43 
applied to pT stage (HR = 4.143, 95% CI 1.48-11.57; P = 0.0033) (Fig. 3A), TB number (HR 44 
 11 
= 5.899, 95% CI 1.875–18.55; P = 0.0006) (Fig. 3D) and the studies’ calculated 1 
Immunoscore (HR = 7.02, 95% CI 2.49–19.84; P = 1.922 x 10-05) (Fig. 3G). Multivariate 2 
Cox regression model (forward stepwise) revealed that this TBISI was the only feature that 3 
added value to the model when pT stage, TB number, Immunoscore, and TBISI were 4 
included (Supplementary Table S4). Finally, the ROC curve showed that the TBISI had the 5 
greatest area under the curve (Area = 0.785, 95% CI 0.629–0.941) when compared to pT 6 
stage or each of the model’s component individually (Supplementary Fig. S2). 7 
Validation of Tumor Budding, Immunoscore and Tumor Bud-Immuno Spatial Index 8 
The TBISI developed from the training set, alongside the Immunoscore and TBs, were 9 
evaluated on two independent validation cohorts; Validation Cohort 1 patients from 10 
Edinburgh hospitals (n = 56) and International Validation Cohort 2 patients from the 11 
NDMCH, Japan (n = 62). Cutoff points calculated from the training set data were directly 12 
applied to the two validation cohorts. Univariate Cox regression and KM analyses were 13 
calculated using the patient data from the two validation cohorts and used to assess the 14 
clinicopathological data, TB number, immunoscore, and the model TBISI (Table 1). pT stage 15 
was significantly associated with patient survival in validation cohort 1 (HR = 5.00, 95% CI 16 
1.52–16.46; P = 0.008) (Fig. 3B), but not in the Japanese validation cohort 2 (Fig. 3C). TB 17 
number was significant in both validation cohort 1 and 2 (HR = 5.29, 95% CI 1.14–24.50; P 18 
= 0.033 and HR = 8.816, 95% CI 2.70–28.82; P = 0.0003) (Fig. 3E and 3F respectively), 19 
whereas the immunoscore was only significant in the validation cohort 1 (HR = 4.72, 95% CI 20 
1.02–21.87; P = 0.047) (Fig. 3H), although trended to significance in validation cohort 2 21 
(Fig. 3I).  22 
TBISI was highly significant on both validation cohorts; Validation Cohort 1 with HR = 23 
12.27, 95% CI 3.52–42.73; p = 8.2 x 10-05 and in Validation Cohort 2 with HR = 15.61, 95% 24 
CI 4.69–51.91; p = 7.42 x 10-06 (Fig. 3K and 3L, respectively). The TBISI demonstrated an 25 
increase in hazard ratio and significance in both validation cohorts than when analyzing the 26 
sum of its parts independently. 27 
  28 
 12 
Discussion 1 
Risk assessment and thus treatment choices for stage II CRC patients are in need of 2 
improvement. A growing awareness exists that the TME contributes to cancer differentiation, 3 
progression, invasion, and metastasis (27–29). In CRC, the two most promising candidate 4 
prognostic features involve two distinct aspects of the TME: tumor budding (2,30–32) and 5 
the Immunoscore (9,10,14,33). Tumor budding represents small clusters of infiltrating cancer 6 
cells within the IM, whereas the Immunoscore quantifies tumor infiltrating lymphocytes 7 
(TILs) within both the IM and the CT. However, these features are predominantly assessed 8 
independently of each other. The question, therefore, arises as to whether these two features 9 
combined augment their individual prognostic significance and whether their association and 10 
spatial relationship adds further prognostic value for stage II CRC patients. The work 11 
presented here utilizes automated image analysis to quantify and compare TBs and TILs 12 
coregistered to the same tissue section.  13 
We report four major findings: first, we have shown significant associations between 14 
clinicopathological factors, CD3
+
 CD8
+
 T-cell densities, and TB number; second, we have 15 
confirmed that Immunoscore and tumor budding are strong independent prognostic factors 16 
for disease specific survival in stage II CRC; third, we have demonstrated that the spatial 17 
interaction between lymphocytes and TBs holds additional prognostic significance; and 18 
finally, a standardized prognostic index was created combining all the above features to 19 
achieve a higher significant cohort stratification than any individual prognostic feature tested. 20 
Emerging technologies in tissue analysis have allowed further understanding of the role of 21 
the TME in disease progression. Automated image analysis has been shown to have a high 22 
potential for unbiased and reproducible assessment of histopathological features in CRC, 23 
such as for TBs, lymphatic vessel invasion (12), and TILs (14), as well as in other disease 24 
types (34,35). To an extent, this is assisted by the advancement of acquiring multiparametric 25 
data from a single tissue section, which can provide a more complete understanding of the 26 
underlying mechanisms within the TME. Even though some multiplex 27 
immunohistochemistry or immunofluorescence methodologies have shown the ability of 28 
high-level multiplexing on a single FFPE tissue sample, the analysis may be restricted to 29 
manually selected regions of interest or through their applications on tissue microarrays (36). 30 
Such methodologies can also be associated with long acquisition times for whole tissue 31 
sections and sequential stitching of image tiles into one large image (37).  In this study we 32 
quantified TILs and TBs coregistered to a single whole slide section through the use of four-33 
plexed immunofluorescence, whole slide scanning, and automated image analysis. This 34 
methodology permitted the colocalization of the four tissue markers, required to quantify the 35 
features measured in this study, across the whole tissue section and at single cell resolution. 36 
Spatial coordinates of each cell type were exported from the same tissue section ensuring 37 
more accurate analysis than is achieved from coregistering serial sections. This methodology 38 
therefore conserves precious tissue, reduces scanning time and cost, while also allowing the 39 
objective analysis of the entire TME and its cellular interactions. 40 
Our results showed that the presence of high CD3
+
 T-cell density correlated with favorable 41 
clinicopathological features, at the IM with the absence of EMLVI and at the CT with 42 
moderate differentiation status and non-mucinous histological type. These data concur well 43 
with prognostic analyses on the propitious impact of overall TIL densities in CRC patients 44 
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(10,38). We also found that a high CD8 T-cell density was correlated with the female gender, 1 
a finding that has previously been shown in invasive CRC by Jang (39). However, the 2 
mechanisms underlying this observation remain unknown. An elevated number of TBs was 3 
significantly associated with advanced pT stage, correlating favorably with previous literature 4 
showing TBs being associated with adverse prognostic features (40–42). These findings 5 
highlight the impairing effect T cells have on tumor progression, while suggesting that high 6 
tumor budding cancers harbor a more aggressive phenotype.  7 
Our data indicate a significant inverse relationship between the densities of TILs and TB 8 
number, which substantiates the work of Zlobec et al. (43), who found the absence of TILs to 9 
be associated with presence of tumor budding. This may suggest that during the transition of 10 
TBs from epithelial to mesenchymal phenotype, they might occupy a niche that may not 11 
illicit an immune response. Indeed, it has been suggested that TBs lose MHC expression 12 
during this transition (7), and others have shown that TB positivity is significantly associated 13 
with PD-L1 positivity (44). The data presented here adds further support to the concept of 14 
TBs having the ability to evade the antitumoral host response and thereby embark on the first 15 
steps of the metastatic cascade. 16 
Despite repeated evidence of tumor budding conferring prognostic significance in CRC 17 
(8,12,42,45), its routine clinical assessment has not yet been established due to the lack of 18 
standardized methodology of assessment. Most studies investigating tumor budding rely upon 19 
the use of manual quantification, often based on subjective selection of high magnification 20 
regions of interest (2). The use of cytokeratin immunohistochemistry has previously shown to 21 
improve the detection of TBs as well as increasing inter-observer reproducibility (30). 22 
Furthermore, cytokeratin immunohistochemistry has been recommended by the International 23 
Tumor Bud Consensus Conference to help TB quantification in challenging cases such as 24 
tumors regions with strong inflammation or ruptured glands (2).  In the current study, tumor 25 
budding was identified by the use of cytokeratin immunofluorescence and quantified by 26 
automated and standardized image analysis across the entire TBROI. Previous studies have 27 
highlighted the difficulty in the qualitative assessment of TBs in circumstances of gland 28 
fragmentation, stromal cells mimicking TBs, inflammation (46), microvesicles, and 29 
membrane fragments that might be cytokeratin-positive (30). In order to address these 30 
concerns, we ensured the presence of whole nuclei (n = 1–4) for the TB identification and 31 
only counted the isolated clusters of cells as buds. Quantifying TBs at the whole TBROI has 32 
the advantage of being representative of the whole invasive margin rather than a manually 33 
selected region of interest. However, our methodology has the potential to “dilute” the 34 
significance of TBs represented by hotspots due to the tumor’s innate heterogeneity. Like 35 
previous semi-quantitative studies (6,42) our quantification methodology reported TB 36 
number and density at the TBROI to be significantly correlated to poor patient survival. 37 
The Immunoscore, proposed by Galon et al. (38,47,48), has been validated in a large 38 
international colon cancer study (14). It is not only a promising prognostic index (11,38), but 39 
it has been shown to be  superior to TNM staging when assessing CRC prognosis (47,49). 40 
This score is based on the quantification of the in situ immune infiltration by the 41 
chromogenic labelling of two sequential tissue sections; one with CD3
+
 T cells and one with 42 
CD8
+
 T cells and quantified in two regions (IM and CT). By applying our automated image 43 
analysis workflow across a single tissue section, our Immunoscore results compared 44 
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favorably with those of Galon et al. (9), showing that a high density of TILs was correlated 1 
with better survival outcomes in stage II CRC. 2 
In order to reflect the dynamic processes present at the tumor front, T lymphocytes in close 3 
(50 and 100 μm) proximity of TBs in a 2-dimensional plot were quantified. Our results 4 
revealed that a high number of T lymphocytes near TBs was associated with better survival. 5 
This supports the theory that TBs represent a heterogeneous subpopulation of cells and, 6 
although hypothesized to be more invasive than well differentiated tumor glands, retain the 7 
potential to be recognized by immune-surveillance mechanisms. This process has previously 8 
been described as “nipping in the bud” (43). This theory was also supported by a study on the 9 
microenvironment of TBs by Lugli et al. (50), reporting high lymphocyte to TB ratio as a 10 
good prognostic factor in patients with CRC and by Lang-Schwarz et al. (51), reporting the 11 
combination of both TILs and tumor budding predicting survival in CRC. Due to the high 12 
complexity and heterogeneity within the whole tissue slide, spatial mapping of specific 13 
features by eye is difficult, subjective, and time consuming. Selected regions of interest to 14 
study this interplay between different features and cells might not represent the spatial 15 
relationships present in the whole tissue. Here we propose a rapid and completely unbiased 16 
method capturing every single event at the single cell resolution and therefore better reporting 17 
on the interactions among TBs and TILs seen at the whole IM. Furthermore, such 18 
methodology can reveal specific patterns that may advance our understanding of the 19 
interactions occurring between cancer cells and their microenvironment.    20 
Multiple features reported from the clinicopathological report and by automated image 21 
analysis demonstrated prognostic significance. In order to reduce the dimensionality of the 22 
data and identify the independently significant features, a Cox regression model with LASSO 23 
regularization was applied to all 32 reported features in this study. This reported a reduced 24 
and independently significant set of 8 features: 4 from the clinicopathological report and 4 25 
from image analysis. This reduced feature set was input for a RF machine learning model, 26 
which consisted of 500 trees. The advantage of feature selection through RF is the thorough 27 
testing of all significant features across multiple models while building in validation. This 28 
machine learning application reported only 4 features with a high mean decrease Gini 29 
coefficient, all of which were exported from image analysis. In order to avoid overfitting of 30 
our model on the training cohort, we included multiple validation steps within the workflow. 31 
Through this, we demonstrate that a model in which patients with a combined low CD3
+
 T-32 
cell density in WTS, low mean number of TILs within 50 μm proximity to TBs, and high TB 33 
number conferred a survival disadvantage compared to any other combination. When a 34 
multivariate forward stepwise Cox regression including pT stage, TB number, Immunoscore, 35 
and TBISI was applied, the only feature reported to significantly add value to the model was 36 
the TBISI, whereas pT stage, TB number, and Immunoscore were not included in the 37 
equation. The new prognostic model of TBISI was then successfully validated across two 38 
independent cohorts, the second of which included patients with different genetic 39 
background, tumor genetic features, and gut microbiota, compared with the first cohort. This 40 
model and its cutpoints did not need to be altered for the Japanese validation cohort despite 41 
the fact that their tissue was sectioned longitudinally compared to the other cohorts that were 42 
cut at a cross-section. pT stage in the Japanese cohort, unlike both Edinburgh ones, was not 43 
significantly correlated with DSS in univariate analysis. This reflects the heterogeneous 44 
nature of stage II CRC disease and further highlights the need for additional methodologies, 45 
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such as the TBISI reported here, to more accurately stratify these patients for both prognostic 1 
reasons and potentially identifying patients that may benefit from adjuvant therapy. 2 
In conclusion, this study reports an automated image analysis–based workflow with the 3 
ability to quantify the tumor-infiltrating immune cells; total T cells (CD3
+
) and cytotoxic T 4 
cells (CD8
+
), and TBs at the invasive front, across a single tissue section. Additionally, 5 
through a machine learning approach, our results show evidence that the spatial association of 6 
lymphocytes and TBs has a high prognostic significance in stage II CRC patients. This 7 
combinational prognostic model demonstrated augmented accuracy and precision over that 8 
gained by either characterizing the lymphocytic infiltration or tumor budding in isolation. 9 
Furthermore, the final model contained no clinical parameters, thus demonstrating the benefit 10 
of automated profiling of the TME to provide a more precise and accurate prognosis. The 11 
methodology completely removes human subjectivity and negates the need for experienced 12 
staff to spend valuable time quantifying complex features across large areas of a whole slide 13 
section. This research can serve as a base for future studies on the prognostic significance of 14 
the interplay between different cell types within the patient’s heterogeneous and heterotypic 15 
TME.  16 
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Table 1. Univariate Cox Regression analysis for clinicopathological data, Immunoscore, Tumor Bud 
(TB) Number and Tumor Bud-Immuno Spatial Index (TBISI) for all three cohorts. Significant features 
(P < 0.05) are shown in bold. Max.tum.diam = Maximum tumor diameter, Ap.node. = Apical node, EMLVI 
= Extramural lymphovascular invasion. 
Freq(%) P Freq(%) P Freq(%) P 
Age 0.233 0.192 0.061
≤70 46(40.4) 24(42.9) 40(64.5)
71-79 32(28.0) 14(25.0) 18(29.0)
≥80 36(31.6) 18(32.1) 4(6.5)
Gender 0.755 0.943 0.253
Male 57(50.0) 34(60.7) 42(67.7)
Female 57(50.0) 22(39.3) 20(32.3)
pT stage 0.006 0.008 0.285
pT3 88(77.2) 46(82.1) 56(90.3)
pT4 26(22.8) 10(17.9) 6(9.7)
Tumour site 0.234 0.293 0.037
Left 38(33.3) 9(16.1) 22(35.5)
Right 43(37.7) 29(51.8) 14(22.6)
Rectal 33(28.9) 18(32.1) 26(41.9)
Differentiation 0.061 0.784 0.240
Moderate 91(79.8) 14(25.0) 20(32.3)
Poor 20(17.5) 8(14.3) 7(11.3)
Well 3(2.6) 34(60.7) 34(54.8)
N/A 0 0 1(1.61)
Max.tum.diam 0.716 0.473
<5 58(50.9) 25(44.6)
≥5 40(35.1) 26(46.4)
N/A 16(14.0) 5(8.9)
Ap.node 0.189 0.035
None 8(7.0) 6(10.7)
≥1 101(88.6) 50(89.3)
N/A 5(4.4)
EMLVI 0.050 0.013
Yes 18(15.8) 3(5.36)
No 96(84.2) 34(60.7)
N/A 0 19(33.9)
Tumour type 0.998 0.126 0.751
Adenocarcinoma 105(92.1) 45(80.4) 56(90.3)
Mucinous 5(4.4) 8(14.3) 5(8.1)
Mixed 4(3.5) 3(5.4) 0
N/A 0 0 1(1.6)
ImageAnalysis
Immunoscore <0.001 0.047 0.057
Low 22 (19.3) 27 (48.2) 20 (32.3)
High 92 (80.7) 29 (51.8) 42 (67.7)
TBNumber <0.001 0.033 <0.001
Low 73 (64.0) 29 (51.8) 48 (77.4)
High 41 (36.0) 27 (48.2) 14 (22.6)
TBISI <0.001 <0.001 <0.001
Low 102 (89.5) 45 (80.4) 56 (90.3)
High 12 (10.5) 11 (19.6) 6 (9.7)
18.75 (6.460-54.430)
5.899 ( 1.875-18.55) 5.289 (1.142-24.500)
4.720 (1.019-21.870)
15.610 (4.692-51.910)
8.816 (2.697-28.820)
3.314 (0.968-11.350)
12.270 (3.524-42.730)
0.366 (0.082-1.641)
0.342 (0.117-1.000)
<0.001 (0-Inf)
7.020 (2.485-19.840)
0.851 (0.308-2.347)
4.143 (1.48-11.57)
0.663 (0.337-1.305)
2.025 (0.968-4.238)
1.224 (0.411-3.646)
Training Cohort (n  = 114) Validation Cohort 1 (n  = 56) Validation Cohort 2 (n  = 62)
Features
HR (95%CI)
Clinicopathological
HR (95%CI) HR (95%CI)
1.466 (0.782-2.747) 2.177 (0.964-4.916)1.603 (0.788-3.260)
2.313 (0.497-10.770)
0.415 (0.092-1.876)0.956 (0.279-3.272)
5.003 (1.521-16.460)
0.620 (0.255-1.510) 2.590 (1.062-6.319)
1.251 (0.252-6.204)
1.590 (0.448-5.637)
0.240 (0.636-0.910)
1.395 (0.178-10.950)
0.113 (0.020-0.636)
1.858 (0.839-4.110)
N/A
N/A
N/A
0.694 (0.378-1.276)
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Feature Total
Freq(%)
Low High Low High Low High Low High Low High Low High Low High
n  = 11 n  = 103 n  = 35 n  = 79 n  = 29 n  = 85 n  = 36 n  = 78 n  = 16 n  = 98 n  = 21 n = 93 n = 73 n  = 41
Age
≤70 46(40.4) 6(5.3) 40(35.1) 14(12.3) 32(28.0) 12(10.5) 34(29.8) 18(15.8) 28(24.6) 6(5.3) 40(35.1) 11(9.7) 35(00.0) 31(27.1) 15(13.2)
71-79 32(28.0) 3(2.6) 59(25.4) 12(10.5) 20(17.5) 10(8.8) 22(19.3) 11(9.7) 21(18.4) 7(6.1) 25(21.9) 7(6.1) 25(21.9) 21(18.4) 11(9.7)
≥80 36(31.6) 2(1.8) 34(29.8) 9(7.9) 27(23.7) 7(6.1) 29(25.4) 7(6.1) 29(25.4) 3(2.6) 33(28.9) 3(2.6) 33(28.9) 21(18.4) 15(13.2)
Gender
Male 57(50) 7(6.1) 50(43.9) 17(14.9) 40(35.1) 15(13.2) 42(36.8) 24(21.1) 33(28.9) 9(7.9) 48(42.1) 15(13.2) 42(36.8) 36(31.6) 21(18.4)
Female 57(50) 4(3.5) 53(46.5) 18(15.8) 39(34.2) 14(12.3) 43(37.7) 12(10.5) 45(39.5) 7(6.1) 50(43.9) 6(5.3) 51(44.7) 37(32.5) 20(17.5)
pT Stage
pT3 88(77.2) 10(8.8) 78(68.4) 23(20.2) 65(57.0) 19(16.7) 69(60.5) 26(22.8) 62(54.4) 11(9.7) 77(67.5) 16(14.0) 72(63.2) 61(53.5) 27(23.7)
pT4 26(22.8) 1(0.9) 25(21.9) 12(10.5) 14(12.3) 10(8.8) 16(14.0) 10(8.8) 16(14.0) 5(4.4) 21(18.4) 5(4.4) 21(18.4) 12(10.5) 14(12.3)
Tumour site
Left 38(33.3) 4(3.5) 34(29.8) 15(13.2) 23(20.2) 11(9.7) 27(23.7) 15(13.2) 23(20.2) 5(4.4) 33(28.9) 8(7.0) 30(26.3) 23(20.2) 15(13.2)
Right 43(37.7) 3(2.6) 40(35.1) 13(11.4) 30(26.3) 10(8.8) 33(28.9) 10(8.8) 33(28.9) 6(5.3) 37(32.5) 7(6.1) 36(31.6) 26(22.8) 17(14.9)
Rectal 33(28.9) 4(3.5) 29(25.4) 7(6.1) 26(22.8) 8(7.0) 25(21.9) 11(9.7) 22(19.3) 5(4.4) 28(24.6) 6(5.3) 27(23.7) 24(21.1) 9(7.9)
Differentiation
Moderate 91(79.8) 8(7.0) 83(72.8) 22(19.3) 69(60.5) 20(17.5) 71(62.3) 28(24.6) 63(55.3) 13(11.4) 78(68.4) 20(17.5) 71(62.3) 61(53.5) 30(26.3)
Poor 20(17.5) 2(1.8) 18(15.8) 12(10.5) 8(7.0) 8(7.0) 12(10.5) 7(6.1) 13(11.4) 2(1.8) 18(15.8) 8(7.0) 12(10.5) 10(8.8) 10(8.8)
Well 3(2.6) 1(0.9) 2(1.8) 1(0.9) 2(1.8) 1(0.9) 2(1.8) 1(0.9) 2(1.8) 1(0.9) 2(1.8) 1(0.9) 2(1.8) 2(1.8) 1(0.9)
Max.tum.diam
<5 58(50.9) 5(4.4) 56(49.1) 14(12.3) 44(38.6) 13(11.4) 45(39.5) 19(16.7) 39(34.2) 6(5.3) 52(45.6) 11(9.7) 47(41.2) 39(34.2) 19(16.7)
≥5 40(35.1) 4(3.5) 36(31.6) 17(14.9) 23(20.2) 11(9.7) 29(25.4) 11(9.7) 29(25.4) 7(6.1) 33(28.9) 7(6.1) 33(28.9) 26(22.8) 14(12.3)
N/A 16(14.0) 2(1.8) 14(12.3) 4(3.5) 12(10.5) 4(3.5) 12(10.5) 6(5.3) 10(8.8) 3(2.6) 13(11.4) 3(2.6) 13(11.4) 8(7.0) 8(7.0)
Ap.node.exam
None 8(7.0) 1(0.9) 7(6.1) 2(1.8) 6(5.3) 3(2.6) 5(4.4) 4(3.5) 4(3.5) 2(1.8) 6(5.3) 3(2.6) 5(4.4) 4(3.5) 4(3.5)
≥1 101(88.6) 10(8.8) 91(79.8) 31(27.2) 70(61.4) 24(21.1) 77(67.5) 30(26.3) 71(62.3) 13(11.4) 88(77.2) 17(14.9) 84(73.7) 65(57.0) 36(31.6)
N/A 5(4.4) 0(0) 5(4.4) 2(1.8) 3(2.6) 2(1.8) 3(2.6) 2(1.8) 3(2.6) 1(0.9) 4(3.5) 1(0.9) 4(3.5) 4(3.5) 1(0.9)
EMLVI
Yes 18(15.8) 4(3.5) 14(12.3) 9(7.9) 9(7.9) 7(6.1) 11(9.7) 8(7.0) 10(8.8) 2(1.8) 16(14.0) 4(3.5) 14(12.3) 12(10.5) 6(5.3)
No 96(84.2) 7(6.1) 89(78.1) 26(22.8) 70(61.4) 22(19.3) 74(64.9) 28(24.6) 68(59.6) 14(12.3) 82(71.9) 17(14.9) 79(69.3) 61(53.5) 35(30.7)
Tumour type
Adenocarcinoma 105(92.1) 9(7.9) 96(84.2) 31(27.2) 74(64.9) 26(22.8) 79(69.3) 35(30.7) 70(61.4) 14(12.3) 91(79.8) 20(17.5) 85(65.8) 66(57.9) 39(34.2)
Mucinous 5(4.4) 2(1.8) 3(2.6) 4(3.5) 1(0.9) 3(2.6) 2(1.8) 1(0.9) 4(3.5) 2(1.8) 3(2.6) 1(0.9) 4(3.5) 4(3.5) 1(0.9)
Mixed 4(3.5) 0(0) 4(3.5) 0(0) 4(3.5) 0(0) 4(3.5) 0(0) 4(3.5) 0(0) 4(3.5) 0(0) 4(3.5) 3(2.6) 1(0.9)
p = 0.800
p = 0.662
IM CT WTS WTSCTIM
TB Number
p = 0.031*
p = 0.467
p = 0.354
p = 0.818
p = 0.417
p = 0.816
p = 0.366
p = 0.839
P  = 0.536
p = 0.697
p = 0.250
p = 0.052
p = 0.338
p = 0.055
p = 0.007*
p = 0.735
p = 0.254
p = 0.341
P  = 0.521
p = 0.233
p = 0.827
p = 0.054
p = 0.049*
p = 0.814
p = 0.316
p = 0.201
p = 0.233
p = 0.023*
p = 0.053
p = 0.736
p = 0.139
p =  0.103
p = 0.153
p = 0.386
p = 0.565
P  = 0.681
p = 0.845
p = 0.283
p = 0.390
p = 0.016*
P  = 0.151
p = 0.857
p = 0.904p = 0.385
p = 0.971
p = 0.579
p = 0.932
p = 0.175 p = 0.625
p = 0.650
p = 0.146
p = 0.854
p = 0.739p = 0.549
p = 0.305
CD3⁺ density (cells/mm²) CD8⁺ density (cells/mm²)
P  =  0.532
p =  0.830
P  = 0.267
p = 0.590 p = 0.030*
P  = 0.164
 
Table 2. Lymphocyte distribution patterns and tumor bud number in relation to clinicopathological characteristics. IM = invasive margin, CT = tumor 
core, WTS = whole tumor section, TB = tumor bud, Max.Tum.Diam = Maximum Tumor Diameter, Ap.Node.Exam = Apical Node Exam, EMLVI = 
Extramural lymphovascular invasion. * Statistical significance, Chi-Square.
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Features 
Coefficients 
LASSO Mean Decrease Gini 
   
CD3
+
 density in WTS -0.0006 5.7932 
   
Mean CD3
+
CD8
+ 
number within 0-50μm of TB  -0.8951 5.4673 
   
TB Number 0.0004 4.7092 
   
CD8
+
 density in CT -0.0004 4.4586 
   
pT 0.8394 1.3724 
   
EMLVI -0.8623 1.1499 
   
Age 0.5791 1.1071 
   
Differentiation 0.4967 0.9728 
Table 3. LASSO penalized Cox proportional hazard regression and Random Forest Gini coefficients 
for the significant features. WTS = whole tumor section, CT = tumor core, TB = tumor bud, EMLVI = 
Extramural lymphovascular invasion.
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Figure Legends: 
Figure 1. Digital image analysis method. A) Full tissue area (yellow line) and invasive front 
(green line) are outlined, pancytokeratin (PanCK), CD3
+
, and CD8
+
 cells annotated in green, 
yellow and red respectively; invasive margin region is highlighted in green (IM) and the 
tumor core region in blue (CT), B) detection and classification of lymphocyte cell type (CD3
+
 
cells in yellow, CD8
+
 cells in red and their colocalization in orange mask), C) Full tissue area 
(yellow line) and Invasive front (green line) are outlined, PanCK, CD3
+
, and CD8
+
 cells 
annotated in green, yellow, and red, respectively; area of tumor bud quantification is 
highlighted in green, D) tumor to stroma segmentation and PanCK cell quantification within 
the tumor areas, E) Proximity Analysis of lymphocytes to tumor buds (TBs). CD3
+
 cells are 
shown in blue, CD8
+
 cells in orange, and TBs in gray. Proximity line series is shown for 
lymphocytes within 50 µm of TBs. 
Figure 2. Spearman correlation matrix for lymphocyte densities and tumor bud 
number. Spearman correlation coefficient is shown for all relationships.  A coefficient with 
either +1 (blue), 0 (white), or -1 (red) value indicates a perfect association, no association, 
and a perfect negative association of ranks, respectively. 
Figure 3. Kaplan Meier survival analysis for pT stage, tumor bud (TB) number, 
immunoscore, and Tumor Bud-Immuno spatial index (TBISI) for training cohort, 
validation cohort 1, and validation cohort 2. (A) pT stage for training cohort, (B) pT stage 
for validation cohort 1, and (C) pT stage for validation cohort 2. (D) TB number for training 
cohort, (E) TB number for validation cohort 1, and (F) TB number for validation cohort 2; 
High represents the group of patients with TB number above the optimal cutoff point 
(1104.0).  Low represents the group of patients with TB Number below the cutoff point. (G) 
Immunoscore for training cohort, (H) Immunoscore for validation cohort 1, and (I) 
Immunoscore for validation cohort 2. High Immunoscore represents the group of patients 
with an Immunoscore > 2, and Low Immunoscore represents the group of patients with an 
Immunoscore ≤ 2. (J) TBISI for training cohort, (K) TBISI for validation cohort 1, and (L) 
TBISI for validation cohort 2. High risk represents the group of patients who have CD3
+
 
density in whole tumor section and mean CD3
+
CD8
+
 cell number within 0–50 μm of TBs 
below the cutoff point (389.6 cells / mm
2
 and 4.1, respectively) and TB number above the 
cutoff point (1104.0). Low risk represents all other patients.  



